After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
Stocks Info
IBIO belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of iBio Inc is $24.07M. A total of 0.73 million shares were traded on the day, compared to an average of 3.08M shares.
In the most recent transaction, Duran Felipe bought 9,191 shares of IBIO for 2.72 per share on Jan 10 ’25. After the transaction, the Chief Financial Officer now owns 11,139 company shares. In a previous transaction on Jan 10 ’25, Brenner Martin bought 9,191 shares at 2.72 per share. IBIO shares that the insider owns now total 18,316.
Among the insiders who bought shares, Banjak Marc acquired of 9,191 shares on Jan 10 ’25 at a per-share price of $2.72. This resulted in the Chief Legal Officer holding 11,066 shares of IBIO after the transaction. In another insider transaction, Arkowitz David bought 18,382 shares at $2.72 per share on Jan 10 ’25. Company shares held by the Director now total 18,382.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, IBIO has a high of $6.89 and a low of $0.56.
As of this writing, IBIO has an earnings estimate of -$0.09 per share for the current quarter. EPS was calculated based on a consensus of 3.0 estimates, with a high estimate of -$0.07 per share and a lower estimate of -$0.13. The company reported an EPS of -$0.48 in the last quarter
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. IBIO’s latest balance sheet shows that the firm has $33.52M in Cash & Short Term Investments as of fiscal 2022. There were $25.77M in debt and $30.44M in liabilities at the time. Its Book Value Per Share was $2.77, while its Total Shareholder’s Equity was $63.48M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for IBIO is Buy with a score of 4.60.
